ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Zymeworks Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$25.54+0.51 (+2.04%)
Close on Oct 19, 2026
- Market cap
- $1.86B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-87.3%+394.0 pts over 5 years
Net margin
-76.6%+387.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +38.9% | -36.4% | +22.2% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -55.1% | -26.7% | |
| Return on assets | – | – | -20.0% | |
| Current ratio | – | – | 5.88 | |
| Capex to revenue | – | 11.1% | 1.4% | |
| Diluted shares | – | 50M | 75M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Zymeworks generated $597.95M from operations and spent $98.29M on capital expenditure, dividends and share buybacks. 27% of that went back into the business.
Generated
$597.95M
Used
$98.29M
Capital expenditure$26.54M27%Dividends$00%Share buybacks$71.75M73%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-76.6%
×Asset turnover0.26×
×Equity multiplier1.33×
=Return on equity, FY2025-26.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -76.6% | 0.26× | 1.33× | -26.7% |
| FY2024 | -160.8% | 0.15× | 1.30× | -30.5% |
| FY2023 | -156.1% | 0.12× | 1.28× | -24.8% |
| FY2022 | 30.1% | 0.79× | 1.40× | 33.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$81.13M
- Cash generatingOperating cash flow above zero-$33.01M
- Return on assets improvedROA up on the prior year-21.1% → -17.5%
- Earnings backed by cashOperating cash flow above net income-$33.01M vs -$81.13M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.40 → 5.88
- No dilutionShare count did not rise76M → 75M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.13 → 0.23